MPTH-41. MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS

Erica H. Bell; Peixin Zhang; Barbara J. Fisher; David R. Macdonald; Joseph P. McElroy; Glenn J Lesser; Jessica Fleming; Arup Chakraborty; Ziyan Liu; Aline Paixao Becker; Denise Fabian; Kenneth D. Aldape; Lynn S. Ashby; Maria Werner-Wasik; Eleanor M Walker; Jean-Paul Bahary; Young Kwok; Michael Yu; Nadia N. Laack; Christopher J Schultz; Heidi J. Gray; H. Ian Robins; Minesh P. Mehta; Arnab Chakravarti

doi:10.1093/neuonc/now212.478

MPTH-41. MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS

Erica H. Bell, Peixin Zhang, Barbara J. Fisher, David R. Macdonald, Joseph P. McElroy, Glenn J Lesser, Jessica Fleming, Arup Chakraborty, Ziyan Liu, Aline Paixao Becker, Denise Fabian, Kenneth D. Aldape, Lynn S. Ashby, Maria Werner-Wasik, Eleanor M Walker, Jean-Paul Bahary, Young Kwok, Michael Yu, Nadia N. Laack, Christopher J SchultzHeidi J. Gray, H. Ian Robins, Minesh P. Mehta, Arnab Chakravarti

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neuro-oncology
Volume	18
DOIs	https://doi.org/10.1093/neuonc/now212.478
State	Published - Nov 1 2016

Disciplines

Oncology

Access to Document

10.1093/neuonc/now212.478License: Unspecified

Cite this

Bell, E. H., Zhang, P., Fisher, B. J., Macdonald, D. R., McElroy, J. P., Lesser, G. J., Fleming, J., Chakraborty, A., Liu, Z., Becker, A. P., Fabian, D., Aldape, K. D., Ashby, L. S., Werner-Wasik, M., Walker, E. M., Bahary, J.-P., Kwok, Y., Yu, M., Laack, N. N., ... Chakravarti, A. (2016). MPTH-41. MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS. Neuro-oncology, 18. https://doi.org/10.1093/neuonc/now212.478

Bell, EH, Zhang, P, Fisher, BJ, Macdonald, DR, McElroy, JP, Lesser, GJ, Fleming, J, Chakraborty, A, Liu, Z, Becker, AP, Fabian, D, Aldape, KD, Ashby, LS, Werner-Wasik, M, Walker, EM, Bahary, J-P, Kwok, Y, Yu, M, Laack, NN, Schultz, CJ, Gray, HJ, Robins, HI, Mehta, MP & Chakravarti, A 2016, 'MPTH-41. MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS', Neuro-oncology, vol. 18. https://doi.org/10.1093/neuonc/now212.478

@article{e4db35ca90354c2cb1e1d236438e408c,

title = "MPTH-41. MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS",

author = "Bell, {Erica H.} and Peixin Zhang and Fisher, {Barbara J.} and Macdonald, {David R.} and McElroy, {Joseph P.} and Lesser, {Glenn J} and Jessica Fleming and Arup Chakraborty and Ziyan Liu and Becker, {Aline Paixao} and Denise Fabian and Aldape, {Kenneth D.} and Ashby, {Lynn S.} and Maria Werner-Wasik and Walker, {Eleanor M} and Jean-Paul Bahary and Young Kwok and Michael Yu and Laack, {Nadia N.} and Schultz, {Christopher J} and Gray, {Heidi J.} and Robins, {H. Ian} and Mehta, {Minesh P.} and Arnab Chakravarti",

note = "BACKGROUND:This study sought to determine the proportion of patients with MGMT promoter methylation within NRG Oncology/RTOG 0424 and its prognostic significance in the setting of high-risk low-grade glioma treated with radiation and temozolomide.METHODS:The MGMT-STP27 prediction model was used to calculate MGMT promoter methylation status from Illumina HM-450K data.",

year = "2016",

month = nov,

day = "1",

doi = "10.1093/neuonc/now212.478",

language = "American English",

volume = "18",

journal = "Neuro-oncology",

}

TY - JOUR

T1 - MPTH-41. MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS

AU - Bell, Erica H.

AU - Zhang, Peixin

AU - Fisher, Barbara J.

AU - Macdonald, David R.

AU - McElroy, Joseph P.

AU - Lesser, Glenn J

AU - Fleming, Jessica

AU - Chakraborty, Arup

AU - Liu, Ziyan

AU - Becker, Aline Paixao

AU - Fabian, Denise

AU - Aldape, Kenneth D.

AU - Ashby, Lynn S.

AU - Werner-Wasik, Maria

AU - Walker, Eleanor M

AU - Bahary, Jean-Paul

AU - Kwok, Young

AU - Yu, Michael

AU - Laack, Nadia N.

AU - Schultz, Christopher J

AU - Gray, Heidi J.

AU - Robins, H. Ian

AU - Mehta, Minesh P.

AU - Chakravarti, Arnab

N1 - BACKGROUND:This study sought to determine the proportion of patients with MGMT promoter methylation within NRG Oncology/RTOG 0424 and its prognostic significance in the setting of high-risk low-grade glioma treated with radiation and temozolomide.METHODS:The MGMT-STP27 prediction model was used to calculate MGMT promoter methylation status from Illumina HM-450K data.

PY - 2016/11/1

Y1 - 2016/11/1

UR - https://academic.oup.com/neuro-oncology/article/2542749/MPTH-41.

U2 - 10.1093/neuonc/now212.478

DO - 10.1093/neuonc/now212.478

M3 - Article

VL - 18

JO - Neuro-oncology

JF - Neuro-oncology

ER -

MPTH-41. MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS

Disciplines

Access to Document

Other files and links

Cite this